Myocard (Doxazosin)

Doxazosin, the active ingredient in Myocard, is a Alpha-1 adrenergic antagonist presented as a tablet for oral use. It treats hypertension and benign prostatic hyperplasia in adults.

GNH USA supplies Myocard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Doxazosin acts on the alpha‑1 adrenergic pathway to lower vascular tone and relax smooth muscle in the prostate.

- Hypertension: reduces peripheral vascular resistance, helping to lower systolic and diastolic blood pressure. - Benign prostatic hyperplasia: relaxes prostatic and bladder‑neck smooth muscle, improving urinary flow and reducing urgency.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or tiredness - Nasal congestion - Peripheral edema - Nausea or upset stomach

Serious or Rare Side Effects: - Marked hypotension, especially after the first dose - Syncope or fainting episodes - Worsening of heart failure symptoms - Severe hepatic dysfunction - Anaphylactic or severe allergic reactions - Priapism (prolonged erection)

Before initiating therapy, clinicians should assess individual risk factors and monitor patients regularly.

- Blood pressure monitoring: check sitting and standing readings after dose adjustments. - Renal and hepatic function: evaluate baseline labs and adjust if impairment is present. - Orthostatic hypotension: advise patients to rise slowly from sitting or lying positions. - Concomitant antihypertensives: consider dose reduction to avoid excessive blood pressure fall. - Discontinuation: taper gradually rather than stopping abruptly to prevent rebound hypertension. - Store at below 25°C: keep in the original pack, protect from moisture.

Doxazosin may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Other alpha‑1 blockers (e.g., prazosin, terazosin) – additive hypotensive effect. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) – increased plasma concentrations. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil) – risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Diuretics – may enhance orthostatic blood pressure drop. - Beta‑blockers – combined effect on heart rate and blood pressure. - NSAIDs – may blunt antihypertensive response. - ACE inhibitors or ARBs – additive blood pressure lowering. - Lithium – possible increase in lithium levels.